Status:
COMPLETED
ONO-4538 Phase I Study in Patients With Solid Tumor
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Advanced Solid Tumors
Recurrent Solid Tumors
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard thera...
Eligibility Criteria
Inclusion
- Male or female ≥ 20 years of age
- Histologically or cytologically confirmed solid tumor
- Patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available
- ECOG Performance Status is 0 to 1
Exclusion
- Current or prior severe hypersensitivity to another antibody product
- Multiple primary cancers
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT02261285
Start Date
October 1 2014
End Date
December 1 2014
Last Update
May 6 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Seongnam-si Clinical Site 105
Seongnam-si, Gyeonggi-do, South Korea
2
Seoul Clinical Site 101
Seoul, South Korea
3
Seoul Clinical Site 102
Seoul, South Korea
4
Seoul Clinical Site 103
Seoul, South Korea